Uday Gupta

I joined the executive team to lead its financial functions including corporate finance, accounting, investor relations as well as capital raising and strategy.

Course Title: Leading Corporate Innovation

My primary focus is Strategic Innovation & Entrepreneurship.

Led various internal and external teams (20+ associates) to oversee creation and execution of new product launches, operational processes and strategy across the Treasury Management product portfolio. ♦ Modernized the Bank’s critical Integrated Payables offering as part of three key strategic initiatives to drive product development, adoption and revenue growth. Negotiated and maintained key vendor relations/partnerships. Leading a team of payables specialists and operations personnel, exceeded 2022 target financial metrics by 140%. ♦ Selected to EVP+ Strategic Committee to provide briefings and influence executive leadership on key industry activities and strategic planning. ♦ Directed client onboarding journey project and process redesign initiatives across the Commercial Bank which led to increased sales associate productivity by five-fold, improved operations’ customer onboarding efficiency metrics by 10%, and customer NPS satisfaction by 25%. ♦ Established and led Treasury Management Product Group, comprised of marketing, sales and operations partners, to facilitate new product launches, iterate product vision and drive business development. Activities included customer segmentation/market data analysis, lead generation/market campaigns, design thinking/voice of customer interviews, product prioritization and development planning.

Led a team of 5 technical consultants providing 24/7 support to 200+ product, operations and national/strategic sales teams that drove innovation and revenue generation for Commercial Card products. ♦ Drove product innovations and launched custom solutions with product, design and tech teams, leading to record MoM and YoY growth for middle-market customers, and improved customer satisfaction. ♦ Established programs to coach and improve performance of 100+ Associates to sell and onboard clients with Capital One’s commercial card products resulting in record-breaking performances and sales figures. ♦ Maintained relationships with key clients by forming a team of product specialists to engage directly with client leadership and key personnel. Accelerated product adoption by three months, time to value (by ~30%) and expanded cross-sell opportunities.

Centerline is a Cleveland Clinic spin-off offering healthcare solutions to bring the next generation of imaging, navigation, predictive analytics and training to minimally invasive surgery. Our first product, IOPS™ (Intra-Operative Positioning System), to be launched in 2018 initially for endovascular cases, delivers 3D visualization and real-time navigation minimizing exposure to high-dosage radiation and toxic contrast dyes. The technology enables greater throughput and lower costs driving better margins (or prevention of losses), improving utilization and profitability of surgical rooms and medical personnel. Recruited by the Chairman of the Board create, execute and manage a compelling product development plan to transform company’s technology assets into multiple business opportunities. ♦ Analyzed competitive landscape and client base, and defined and implemented a product development roadmap ensuring competitive advantages as well as timely launch of new point of care and software solutions. ♦ Responsible for developing and executing go-to-market sales and marketing plan to quickly monetize technology. ♦ Prepared business model that included financial models, valuation, and competitive analysis. Developing and managing relationships with Venture Capital communities in North America and Europe. ♦ Led a team of six professionals to define and execute a global clinical research/trial strategy to meet regulatory compliance and 510(k) clearance. Managed and optimized budget to ensure allocation of funds and personnel.

A bio-agriculture firm focused on the commercialization of prebiotic fibers to improve the quality and health of animals (companion and commercial) and humans. Blue Prairie, originally ProteiosBio, directly addresses the growing demand from consumers for natural, high fiber, gluten-free, non-GMO, diabetic-friendly prebiotic foods and beverages. Founded, funded and lead a tight-knit team to enter the $77B functional flour market with a proprietary prebiotic-rich chicory root flour for both B2B and B2C markets. ♦ Raised over $3M in debt and equity financing from institutional and strategic venture capital. Prepared term sheet, business plan, investor pitch deck, financial models and valuation to present to over 30 firms in the Americas and Europe. Awarded ~$1.5M in R&D grants from the Commonwealth of Virginia and the State of Nebraska. Managed cashflow to extend working capital and operations by over one year. ♦ Led cross-functional team using design thinking to identify and develop core product. Aligned corporate resources and priorities accordingly. ♦ Negotiated and executed over a dozen contracts with seed breeder, growers, and food producers. Ensured exclusive terms giving company first-market mover advantage and sole access to strategic assets across value chain. ♦ Grew operations from field trials to over 200 acres of commercial crop as well as oversaw the build-out of a 10,000 sq. ft. processing plant. Increased production throughput by 500% without increasing working capital. In parallel, led commercialization efforts by aligning and overseeing product development to meet market demands for both traditional and eCommerce channels. ♦ Developed a marketing strategy that included partnering with ingredient suppliers, including several of the largest branded Consumer Packaged Goods companies, and private label companies to ease market entry and accelerate product acceptance.

GCS is a biotechnology firm focused on the commercialization of three-dimensional cell culture technologies to improve the quality and delivery of cell and tissue cultures for cell-based and clinical diagnostic screening, drug discovery, biomanufacturing, and regenerative therapeutics. Initially invited to start and manage a biology-based company through UVA’s Batten Incubator supporting drug discovery and regenerative medicine industries. Led it through multiple stages of international growth. ♦ Product Management: Analyzed market opportunities, developed and introduced over 20 proprietary products as well as in-licensed over 50 OEM products offering comprehensive solutions to customers globally. ♦ Capital Financing: Led company through several rounds of financing to support product development, operations, product launch and global distribution. ♦ Operations: Managed day-to-day in-house activities including budgets/expense controls, intellectual property management, sales and marketing initiatives, vendor and customer relationships, employee hiring and training, and operational support including scientific research and development. ♦ Business Modeling: Defined and implemented a business model that allowed company to focus on core products/innovations while maximizing global market penetration and sales. Optimized value chain while establishing a global network of distributors in N. America, Europe, Asia and Australia driving on average 40% year over year sales growth for 5 consecutive years. ♦ Contract Negotiations: Negotiating strategic alliances with several International lab automation and reagent companies to build and/or sell GCS’ cell culture system and reagents.

Standard & Poor's Structured Finance team provides rating/forward-looking opinions about the credit worthiness of issuers and obligations. Working as an analyst, evaluated, among other things, the credit quality, likelihood of default, and potential risks in securitizations for various asset classes, including: - Asset-Backed Securities - Structured Credit Securities - Commercial Mortgage-Backed Securities - Residential Mortgage-Backed Securities - Servicer Evaluations